Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects
Christian Liedtke,Tom Luedde,Tilman Sauerbruch,D. Scholten,Konrad L. Streetz,Frank Tacke,Rene Tolba,Christian Trautwein,Jonel Trebicka,Ralf Weiskirchen +9 more
TL;DR: This review gives an update on current animal models, techniques and underlying pathomechanisms with the aim of fostering a critical discussion of the limitations and potential of up-to-date animal experimentation.
Journal ArticleDOI
Identification of driver genes in hepatocellular carcinoma by exome sequencing.
Sean P. Cleary,William R. Jeck,Xiaobei Zhao,Kui Chen,Sara R. Selitsky,Gleb L. Savich,Ting Xu Tan,Michael C. Wu,Gad Getz,Michael S. Lawrence,Joel S. Parker,Jinyu Li,Scott Powers,Hyeja Kim,Sandra Fischer,Maha Guindi,Maha Guindi,Anand Ghanekar,Derek Y. Chiang +18 more
TL;DR: The NFE2L2‐KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC, with significantly affected gene families include the nucleotide‐binding domain and leucine‐rich repeat‐containing family, calcium channel subunits, and histone methyltransferases.
Journal ArticleDOI
Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.
Jens U. Marquardt,Luis Enrique Gómez-Quiroz,Lucrecia O. Arreguin Camacho,Federico Pinna,Yun-Han Lee,Mitsuteru Kitade,Mayrel Palestino Domínguez,D Castven,Kai Breuhahn,Elizabeth A. Conner,Peter R. Galle,Jesper B. Andersen,Valentina M. Factor,Snorri S. Thorgeirsson +13 more
TL;DR: It is demonstrated that blocking NF-κB can specifically target CSC populations and suggested that HCCs with poor prognosis and progenitor features are most likely to benefit from NF-σκB inhibition.
Journal ArticleDOI
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.
TL;DR: The current and future medical and surgical management of HCC is provided, including sorafenib, which is the most commonly used systemic therapy; although, it has been shown to only minimally impact patient survival by several months.
Journal ArticleDOI
Hypoxia‐mediated sorafenib resistance can be overcome by EF24 through Von Hippel‐Lindau tumor suppressor‐dependent HIF‐1α inhibition in hepatocellular carcinoma
Yingjian Liang,Tongsen Zheng,Ruipeng Song,Jiabei Wang,Dalong Yin,Luoluo Wang,Haitao Liu,Lan-tian Tian,Xiang Fang,Xianzhi Meng,Hongchi Jiang,Jiaren Liu,Lianxin Liu +12 more
TL;DR: This study tested the hypothesis that hypoxia caused by the antiangiogenic effects of sustained sorafenib therapy could induce sorafinib resistance as a cytoprotective adaptive response, thereby limiting sorAFenib efficiency, and found that sustained SorafenIB therapy led to increased intratumor hypoxIA, which was associated with sorafanib sensitivity in HCC subcutaneous mice tumor models.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more